The role of abiraterone acetate in the management of prostate cancer: A critical analysis of the literature

European Urology

Volumn 60, Issue 2, 2011, Pages 270-278

  Sonpavde, Guru ^a,b   Attard, Gerhardt ^c   Bellmunt, Joaquim ^d   Mason, Malcolm D ^e   Malavaud, Bernard ^f   Tombal, Bertrand ^g   Sternberg, Cora N ^h  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d HOSPITAL DEL MAR   (Spain)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

17 Hydroxylase; 17,20 Lyase; Abiraterone acetate (AA); Castration resistant prostate cancer (CRPC); CYP17; Secondary hormonal therapy

Indexed keywords

17 HYDROXYPREGNENOLONE; ABIRATERONE ACETATE; ALDOSTERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIONE; CORTICOSTERONE; CORTICOTROPIN; CORTODOXONE; CYTOCHROME P450 17; DIHYDROTACHYSTEROL; DOCETAXEL; HYDROCORTISONE; HYDROXYPROGESTERONE; KETOCONAZOLE; PRASTERONE; PREDNISONE; PREGNENOLONE; PROGESTERONE; TESTOSTERONE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MECHANISM; FLUID RETENTION; HUMAN; HYPERTENSION; HYPOKALEMIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 79959545655     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.04.032     Document Type: Review

References (49)

1. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
2. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
3. Y. Chen, N.J. Clegg, and H.I. Scher Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol 10 2009 981 991
4. G. Attard, C.S. Cooper, and J.S. de Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 2009 458 462
5. A. Zoubeidi, A. Zardan, and E. Beraldi Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity Cancer Res 67 2007 10455 10465 (Pubitemid 350070821)
6. A.H. Reid, G. Attard, E. Barrie, and J.S. de Bono CYP17 inhibition as a hormonal strategy for prostate cancer Nat Clin Pract Urol 5 2008 610 620
7. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648 (Pubitemid 41528150)
8. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
9. T. Ueda, N. Bruchovsky, and M.D. Sadar Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways J Biol Chem 277 2002 7076 7085 (Pubitemid 34959964)
10. D. Compagno, C. Merle, and A. Morin SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas PLoS One 2 2007 e1006
11. J. Morote, A. Orsola, and J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295 (Pubitemid 47368393)
12. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, and N.J. Maitland Prospective identification of tumorigenic prostate cancer stem cells Cancer Res 65 2005 10946 10951 (Pubitemid 41713363)
13. Y.E. Whang, X. Wu, and H. Suzuki Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proc Natl Acad Sci U S A 95 1998 5246 5250 (Pubitemid 28208583)
14. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res 69 2009 4937 4940
15. P.R. Dillard, M.F. Lin, and S.A. Khan Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol Mol Cell Endocrinol 295 2008 115 120
16. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
17. E.A. Mostaghel Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res 67 2007 5033 5041 (Pubitemid 46910214)
18. J. Edwards, N.S. Krishna, K.M. Grigor, and J.M. Bartlett Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br J Cancer 89 2003 552 556 (Pubitemid 37026442)
19. C.W. Gregory, B. He, and R.T. Johnson A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res 61 2001 4315 4319 (Pubitemid 32685750)
20. C.W. Gregory, R.T. Johnson Jr., J.L. Mohler, F.S. French, and E.M. Wilson Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 2001 2892 2898 (Pubitemid 32691931)
21. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 2008 5469 5477
22. M.P. Steinkamp, O.A. O'Mahony, and M. Brogley Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy Cancer Res 69 2009 4434 4442
23. M.E. Taplin, B. Rajeshkumar, and S. Halabi Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 J Clin Oncol 21 2003 2673 2678 (Pubitemid 46606310)
24. E.J. Small, and S. Srinivas The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer Cancer 76 1995 1428 1434
25. H.I. Scher, C. Liebertz, and W.K. Kelly Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 15 1997 2928 2938 (Pubitemid 27330021)
26. M. Nakabayashi, M.M. Regan, and D. Lifsey Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer BJU Int 96 2005 783 786 (Pubitemid 41391380)
27. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033 (Pubitemid 41095034)
28. M.D. Galsky, K. Simon, and G. Sonpavde Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer Ann Oncol 20 2009 965 966
29. C.J. Ryan Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study Clin Cancer Res 13 2007 2030 2037 (Pubitemid 46649869)
30. J. Shamash, J. Stebbing, and C. Sweeney A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer Cancer 116 2010 3595 3602
31. D.R. Rovner, J.W. Conn, E.L. Cohen, F.G. Berlinger, D.C. Kem, and D.L. Gordon 17 alpha-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis Acta Endocrinol (Copenh) 90 1979 490 504 (Pubitemid 9141963)
32. M. Costa-Santos, C.E. Kater, and R.J. Auchus Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency J Clin Endocrinol Metab 89 2004 49 60 (Pubitemid 38183859)
33. S.E. Barrie, G.A. Potter, P.M. Goddard, B.P. Haynes, M. Dowsett, and M. Jarman Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase) J Steroid Biochem Mol Biol 50 1994 267 273 (Pubitemid 24309119)
34. M. Jarman, S.E. Barrie, and J.M. Llera The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors J Med Chem 41 1998 5375 5381 (Pubitemid 29031321)
35. M.G. Rowlands, S.E. Barrie, and F. Chan Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis J Med Chem 38 1995 4191 4197
36. C. Jagusch Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure Bioorg Med Chem 16 2008 1992 2010 (Pubitemid 351226569)
37. M.A. Pinto-Bazurco Mendieta, M. Negri, C. Jagusch, U. Muller-Vieira, T. Lauterbach, and R.W. Hartmann Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer J Med Chem 51 2008 5009 5018
38. A. O'Donnell, I. Judson, and M. Dowsett Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br J Cancer 90 2004 2317 2325 (Pubitemid 38961894)
39. G. Attard, A.H. Reid, and T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
40. C.J. Ryan, M.R. Smith, and L. Fong Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28 2010 1481 1488
41. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
42. A.H. Reid, G. Attard, and D.C. Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
43. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
44. De Bono J, Logothetis CJ, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel based chemotherapy: results of COU-AA-301, a randomized double blind placebo-controlled phase III study [abstract LBA5]. Abstract presented at: European Society for Medical Oncology Congress; October 8-12, 2010; Milan, Italy.
45. Scher HI, Logothetis C, Molina A, et al. Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. Genitourinary Cancers (Symposium abstract 4). Genitourinary Cancer Symposium. Presented February 17, 2011; Orlando, Florida, USA.
46. P.J. Van Veldhuizen, G. Reed, A. Aggarwal, J. Baranda, M. Zulfiqar, and S. Williamson Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study Cancer 98 2003 1855 1862 (Pubitemid 37310228)
47. G. Attard, A.H. Reid, and J.S. de Bono Abiraterone acetate is well tolerated without concomitant use of corticosteroids J Clin Oncol 28 2010 e560 e561 author reply e562
48. C. Palmberg, P. Koivisto, L. Kakkola, T.L. Tammela, O.P. Kallioniemi, and T. Visakorpi Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer J Urol 164 2000 1992 1995
49. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422